Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Apr 26, 2015; 3(2): 97-117
Published online Apr 26, 2015. doi: 10.13105/wjma.v3.i2.97
Published online Apr 26, 2015. doi: 10.13105/wjma.v3.i2.97
Meta-analysis of single strain probiotics for the eradication of Helicobacter pylori and prevention of adverse events
Lynne V McFarland, Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195, United States
Lynne V McFarland, Health Services Research and Development, VA Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA 98101, United States
Peter Malfertheiner, Universitatsklinikum Magdeburg AOR, 39120 Magdeburg, Germany
Ying Huang, Lin Wang, Children’s Hospital of Fudan University, Shanghai 201102, China
Author contributions: McFarland LV, Malfertheiner P, Huang Y and Wang L reviewed, scored papers and were involved in the manuscript preparation; McFarland LV designed the study, did literature search and analyzed the data.
Conflict-of-interest: Lynne V McFarland has received fees as a speaker (Biocodex, France and Lallemand, France) and is on the scientific advisory board of BioK+, Canada. Peter Malfertheiner has received speaker fees from Biocodex and is on the scientific advisor board of Danone. Ying Huang and Lin Wang have no conflicts of interest. No authors are employed by or have stock or equity in any company manufacturing probiotics.
Data sharing: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Lynne V McFarland, PhD, Health Services Research and Development, VA Puget Sound Health Care System, Department of Veterans Affairs, Metropolitan Park West, 1100 Olive Way #1400, Seattle, WA 98101, United States. lvmcfarl@u.washington.edu
Telephone: +1-206-2771780 Fax: +1-206-7642935
Received: October 22, 2014
Peer-review started: October 24, 2014
First decision: December 26, 2014
Revised: January 3, 2015
Accepted: January 15, 2015
Article in press: January 19, 2015
Published online: April 26, 2015
Processing time: 187 Days and 10.3 Hours
Peer-review started: October 24, 2014
First decision: December 26, 2014
Revised: January 3, 2015
Accepted: January 15, 2015
Article in press: January 19, 2015
Published online: April 26, 2015
Processing time: 187 Days and 10.3 Hours
Core Tip
Core tip: A meta-analysis was conducted (1960-2014) for randomized clinical trials testing single strained probiotics as an adjunct to standard Helicobacter pylori (H. pylori) eradication therapy. Of the single strains with multiple trials, only one significantly improved H. pylori eradication rates {Saccharomyces boulardii (S. boulardii) I-745 [pooled relative risks (pRR) = 1.11, 95%CI: 1.07-1.16)]}, while two strains significantly reduced the rate of antibiotic-associated diarrhea [S. boulardii I-745 (pRR = 0.47, 95%CI: 0.37-0.60) and Lactobacillus rhamnosus GG (pRR = 0.29, 95%CI: 0.17-0.48)]. None of the other four probiotic strains improved H. pylori therapy (C. butyricum, L. acidophilus, L. reuteri, L. casei).